| Literature DB >> 25126115 |
Nan Wu1, Xiaoling Cai2, Kuanping Ye1, Yintao Li1, Min He1, Weiwei Zhao1, Renming Hu1.
Abstract
BACKGROUND: Cardiac autonomic neuropathy (CAN) is a common complication of type 2 diabetes mellitus (T2DM). Brachial-ankle pulse wave velocity (baPWV) is known to be a good surrogate marker of vascular damages. The goal of this study was to investigate the relationship between BaPWV and CAN in T2DM.Entities:
Keywords: Brachial-ankle pulse wave velocity; Cardiac autonomic neuropathy; Type 2 diabetes
Year: 2014 PMID: 25126115 PMCID: PMC4132900 DOI: 10.1186/1758-5996-6-82
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Clinical and biochemical characteristics of participants
| Characteristic | N = 148 |
|---|---|
| cardiovascular autonomic neuropathy(%) | 78(52.7) |
| Age(years) | 59.8 ± 7.8 |
| Male,n(%) | 80(54.0) |
| Current smoker, n (%) | 43(29.0) |
| Alcohol consumption, n (%) | 37(25.0) |
| Hypertension, n (%) | 81(54.7) |
| Use of β-Blockers | 34(22.9) |
| Use of ACEI/ARB | 67(45.3) |
| Use of CCB | 48(32.4) |
| Other antihypertensives | 14(9.5) |
| Express as median(years) | 6.0(2.0-11.0) |
| BMI(kg/m2) | 24.4 ± 3.4 |
| Waist-to-hip ratio | 0.94(0.90-0.99) |
| systolic blood pressure(mmHg) | 134.2 ± 18.1 |
| diastolic blood pressure(mmHg) | 78.3 ± 10.6 |
| HbA1c(%) | 8.0 ± 1.9 |
| fasting glucose(mmol/l) | 7.1(5.8-9.2) |
| Creatinine (μmol/L) | 62.0(53.0-78.0) |
| eGFR( ml/min/1.73 m2) | 107.0 ± 32.8 |
| total cholesterol(mmol/l) | 4.89 ± 1.52 |
| Triglyceride(mmol/l) | 1.61(1.05-2.34) |
| LDL cholesterol(mmol/l) | 2.84(2.29-3.60) |
| HDL cholesterol(mmol/l) | 1.09(0.93-1.33) |
| ACR(mg/g) | 12.02(7.18-19.54) |
| baPWV(cm/sec) | 1665.5(1482.0-1940.0) |
| Diabetic retinopathy, n (%) | 25(16.9) |
| Diabetic peripheral neuropathy, n (%) | 46(31.1) |
| NSS score | 5.0(2.0-6.0) |
| NDS score | 4.0(2.0-5.0) |
| Diabetic nephropathy, n (%) | 33(22.2) |
BMI, body mass index; eGFR, modification of diet in renal disease study-glomerular filtration rate; ACR, albumin-to-creatinine ratio;ACEI/ARB, angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers; CCB, Calcium channel blocker; NSS, neuropathy symptom score; NDS, neuropathy disability score.
Data are means SD, median (25-75%), or number (percent).
Correlation between baPWV and other clinical variables
| Variable | Correlation coefficients | P |
|---|---|---|
| Age | 0.404 | 0.001 |
| Duration of diabetes* | 0.141 | 0.095 |
| BMI | 0.124 | 0.134 |
| Waist-to-hip ratio* | 0.081 | 0.327 |
| systolic blood pressure | 0.654 | 0.001 |
| diastolic blood pressure(mmHg) | 0.327 | 0.001 |
| HbA1c | -0.010 | 0.900 |
| fasting glucose* | 0.061 | 0.477 |
| Creatinine* | 0.020 | 0.832 |
| eGFR | -0.128 | 0.122 |
| total cholesterol | -0.038 | 0.694 |
| Triglyceride* | 0.151 | 0.116 |
| LDL cholesterol* | -0.028 | 0.779 |
| HDL cholesterol* | -0.073 | 0.459 |
| ACR(mg/g) | -0.028 | 0.781 |
Data are shown as Pearson correlation coefficients (r).
baPWV was log-transformed when statistics were applied.
*Denotes the variables that were log-transformed when statistics were applied.
Comparison of clinical characteristics according the presence of cardiac autonomic neuropathy
| Variable | without CAN (n = 70) | with CAN (n = 78) | P value |
|---|---|---|---|
| Age(years) | 57.6 ± 7.6 | 61.8 ± 7.4 | 0.001 |
| Male,n(%) | 41(58.6) | 39(50.0) | 0.296 |
| Current smoker, n (%) | 17(24.3) | 26(33.3) | 0.226 |
| Alcohol consumption, n (%) | 15(21.4) | 22(28.2) | 0.342 |
| Hypertension, n (%) | 35(50.0) | 46(59.0) | 0.273 |
| Use of β-Blockers | 16(22.9) | 18(23.1) | 0.856 |
| Use of ACEI/ARB | 32(45.7) | 35(44.9) | 0.746 |
| Use of CCB | 22(31.4) | 26(33.3) | 0.246 |
| Other antihypertensives | 8(11.4) | 6(7.7) | 0.168 |
| Duration of diabetes(years)* | 6.0(2.0-10.3) | 6.0(2.0-11.0) | 0.815 |
| BMI(kg/m2) | 23.9 ± 3.1 | 25.0 ± 3.6 | 0.042 |
| Waist-to-hip ratio* | 0.94(0.88-0.99) | 0.94(0.90-1.00) | 0.849 |
| systolic blood pressure(mmHg) | 132.2 ± 16.4 | 136.0 ± 19.4 | 0.207 |
| diastolic blood pressure(mmHg) | 78.7 ± 11.0 | 78.0 ± 10.3 | 0.691 |
| HbA1c(%) | 7.9 ± 1.7 | 8.1 ± 2.0 | 0.613 |
| fasting glucose(mmol/l)* | 7.1(6.0-9.1) | 6.7(5.8-9.3) | 0.750 |
| Creatinine (μmol/L)* | 64.0(52.0-78.0) | 59.0(53.0-79.5) | 0.519 |
| eGFR( ml/min/1.73 m2) | 107.8 ± 25.4 | 103.0 ± 31.1 | 0.303 |
| total cholesterol(mmol/l) | 4.83 ± 1.92 | 4.94 ± 1.16 | 0.709 |
| Triglyceride(mmol/l)* | 1.54(0.99-2.69) | 1.75(1.10-2.33) | 0.510 |
| LDL cholesterol(mmol/l)* | 2.84(2.11-3.60) | 2.83(2.37-3.60) | 0.632 |
| HDL cholesterol(mmol/l)* | 1.10(0.92-1.30) | 1.09(0.94-1.36) | 0.693 |
| ACR(mg/g) | 10.90(6.87-24.72) | 15.41(7.60-23.67) | 0.472 |
| baPWV(cm/sec)* | 1584.0(1446.1-1812.63) | 1722.0(1493.9-2040.8) | 0.011 |
| Diabetic retinopathy, n (%) | 10(14.3) | 15(19.2) | 0.423 |
| Diabetic peripheral neuropathy, n (%) | 16(22.9) | 30(38.5) | 0.041 |
| NSS score | 3.0(2.0-5.0) | 5.0(3.0-6.0) | 0.036 |
| NDS score | 3.0(2.0-4.0) | 4.0(2.0-5.0) | 0.065 |
| Diabetic nephropathy, n (%) | 16(22.9) | 17(21.8) | 0.877 |
BMI, body mass index; eGFR, modification of diet in renal disease study-glomerular filtration rate.
Data are means SD, median (25-75%), or number (percent).
*Denotes the variables that were log-transformed when statistics were applied.
Relationships between multiple risk factors and cardiovascular autonomic neuropathy
| Variable | Model A | Model B | ||
|---|---|---|---|---|
| Adjusted odds ratio (95% CI) | P | Adjusted odds ratio (95% CI) | P | |
| Age > 60 years, no vs yes | 2.247(1.160-4.349) |
| 2.837(1.365-5.897) |
|
| Gender(male) | 1.513(0.776-2.951) | 0.225 | 1.692(0.840-3.406) | 0.141 |
| Duration of diabetes(per decade) | 0.848(0.474-1.517) | 0.578 | 0.832(0.454-1.523) | 0.550 |
| BMI(per kg/m2) | 0.888(0.800-0.985) | 0.024 | 0.888(0.798-0.988) | 0.029 |
| Waist-to-hip ratio* | 2.205(0.014-353.823) | 0.760 | 2.119(0.320-14.033) | 0.436 |
| systolic blood pressure(per 10 mmHg) | 1.008(0.989-1.027) | 0.391 | 1.017(0.996-1.038) | 0.108 |
| diastolic blood pressure(per 10 mmHg) | 0.997(0.966-1.028) | 0.840 | 0.977(0.919-1.039) | 0.457 |
| Current smoker, no vs yes | 1.660(0.792-3.479) | 0.179 | 1.331(0.599-2.955) | 0.482 |
| Alcohol consumption, no vs yes | 1.521(0.702-3.292) | 0.287 | 1.474(0.660-3.293) | 0.344 |
| Hypertension, no vs yes | 1.262(0.645-2.468) | 0.497 | 1.563(0.767-3.183) | 0.219 |
| HbA1c(per 1%) | 1.115(0.929-1.338) | 0.244 | 1.091(0.905-1.314) | 0.550 |
| fasting glucose(per 1 mmol/l)* | 1.020(0.922-1.128) | 0.700 | 0.594(0.176-2.007) | 0.401 |
| Creatinine (per 1 μmol/L)* | 0.954(0.230-3.950) | 0.948 | 1.119(0.256-4.882) | 0.881 |
| eGFR( per 1 ml/min/1.73 m2) | 0.999(0.987-1.011) | 0.874 | 0.995(0.982-1.008) | 0.465 |
| total cholesterol(per 1 mmol/l) | 1.046(0.807-1.355) | 0.735 | 1.024(0.778-1.349) | 0.864 |
| Triglyceride(per 1 mmol/l)* | 0.823(0.462-1.469) | 0.511 | 0.969(0.524-1.795) | 0.921 |
| LDL cholesterol(per 1 mmol/l)* | 1.405(0.426-4.634) | 0.576 | 1.470(0.423-5.113) | 0.545 |
| HDL cholesterol(per 1 mmol/l)* | 0.740(0.242-2.267) | 0.598 | 0.632(0.196-2.034) | 0.442 |
| ACR(mg/g) | 1.000(0.999-1.000) | 0.574 | 1.000(0.999-1.000) | 0.538 |
| baPWV(cm/sec)* | 6.117(1.032-36.245) | 0.046 | 8.496(1.216-59.348) | 0.031 |
| Diabetic retinopathy, no vs yes | 1.431(0.586-3.493) | 0.431 | 1.589(0.634-3.984) | 0.323 |
| Diabetic peripheral neuropathy, no vs yes | 2.071(0.994-4.315) | 0.052 | 2.672(1.155-6.183) | 0.022 |
| Diabetic nephropathy, no vs yes | 0.940(0.426-2.072) | 0.878 | 1.087(0.459-2.575) | 0.849 |
Data were obtained from a multivariate regression model.
Model A, adjusted for age; Model B, adjusted for age, gender, smoking, drinking, duration of diabetes, BMI, HbA1c, systolic blood pressure, the presence of diabetic retinopathy.
*Denotes the variables that were log-transformed when statistics were applied.
Figure 1The levels baPWV according to the number of abnormal CARTs. Data are shown as means ± SE after adjustment for age (per decade), gender, smoking, duration of diabetes; P =0.002 for trend.
Mean baPWV value in patients with normal, borderline, and abnormal autonomic nervous function tests
| Normal result | Borderline result | Abnormal result |
| ||
|---|---|---|---|---|---|
| baPWV(cm/sec)* | HR variation during deep breathing | 1537.50(1392.88-1863.00) | 1649.25(1480.75-1815.50) | 1728.25(1524.00-2029.38)## | 0.002 |
| HR response to standing | 1623.75(1444.38-1890.00) | 1757.25(1552.75-2012.75) | 1825.00(1509.88-2020.63)# | 0.046 | |
| Valsalva maneuver | 1666.25(1459.88-1945.75) | 1642.00(1512.25-2006.50) | 1669.50(1445.25-1934.75) | 0.392 | |
| postural BP change | 1651.75(1486.88-1937.00) | 1661.25(1426.50-1983.50) | 1775.86(1568.67-2043.00) | 0.471 | |
| Sustained handgrip test | 1656.00(1500.13-1947.50) | 1540.75(1329.37-1939.63) | 1777.25(1509.88-1943.38) | 0.835 |
HR, heart rate; BP, blood pressure.
*Denotes the variables that were log-transformed when statistics were applied.
#P < 0.05, ##P < 0.01, for comparisons of baPWV values between abnormal, borderline and normal test.